Evidence map›Paper›PMID 18840295›Full record

ArticleBMC biotechnology2008

A construct with fluorescent indicators for conditional expression of miRNA.

Linghua Qiu, Hongyan Wang, Xugang Xia, Hongxia Zhou, Zuoshang Xu

Open access · goldAbstract read
In one paragraph

Article in BMC biotechnology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 41 citations in OpenAlex.

  1. miRNA modules for precise, tunable control of gene expression.bioRxiv : the preprint server for biology · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. MicroRNAs in orthopaedic research: Disease associations, potential therapeutic applications, and perspectives.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2018
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Partial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis.Proceedings of the National Academy of Sciences of the United States of America · 2014
    Article
  14. Article
  15. Gap junction-dependent homolog avoidance in the developing CNS.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2013
    Article
  16. Article
  17. Strategies for designing transgenic DNA constructs.Methods in molecular biology (Clifton, N.J.) · 2013
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Linghua QiuDepartment of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, 364 Plantation St, Worcester, MA 01605, USA. Linghua.Qiu@umassmed.edu
Hongyan Wang
Xugang Xia
Hongxia Zhou
Zuoshang Xu
University of Massachusetts Chan Medical School · US

Funding

Understanding mechanism and therapy of ALS using RNAiR01NS048145 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI XU, ZUOSHANG · 2004 to 2008
$1.8M
Reverse genetics using RNAi in non-mouse mammalsR21AG028548 · NIA · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI XU, ZUOSHANG · 2007 to 2008
$362k
NIA NIH HHS R21 AG028548NINDS NIH HHS R01 NS048145NINDS NIH HHS R01NS048145
6 · The paper itself

Abstract

backgroundTransgenic RNAi holds promise as a simple, low-cost, and fast method for reverse genetics in mammals. It may be particularly useful for producing animal models for hypomorphic gene function. Inducible RNAi that permits spatially and temporally controllable gene silencing in vivo will enhance the power of transgenic RNAi approach. Furthermore, because microRNA (miRNA) targeting specific genes can be expressed simultaneously with protein coding genes, incorporation of fluorescent marker proteins can simplify the screening and analysis of transgenic RNAi animals.

resultsWe sought to optimally express a miRNA simultaneously with a fluorescent marker. We compared two construct designs. One expressed a red fluorescent protein (RFP) and a miRNA placed in its 3' untranslated region (UTR). The other expressed the same RFP and miRNA, but the precursor miRNA (pre-miRNA) coding sequence was placed in an intron that was inserted into the 3'-UTR. We found that the two constructs expressed comparable levels of miRNA. However, the intron-containing construct expressed a significantly higher level of RFP than the intron-less construct. Further experiments indicate that the 3'-UTR intron enhances RFP expression by its intrinsic gene-expression-enhancing activity and by eliminating the inhibitory effect of the pre-miRNA on the expression of RFP. Based on these findings, we incorporated the intron-embedded pre-miRNA design into a conditional expression construct that employed the Cre-loxP system. This construct initially expressed EGFP gene, which was flanked by loxP sites. After exposure to Cre recombinase, the transgene stopped EGFP expression and began expression of RFP and a miRNA, which silenced the expression of specific cellular genes.

conclusionWe have designed and tested a conditional miRNA-expression construct and showed that this construct expresses both the marker genes strongly and can silence the target gene efficiently upon Cre-mediated induction of the miRNA expression. This construct can be used to increase the efficiency of making cell lines or transgenic animals that stably express miRNA targeting specific genes.

Indexed as

3' Untranslated RegionsExtracellular Matrix ProteinsFluorescent DyesGene Expression RegulationGreen Fluorescent ProteinsIntegrasesIntronsKetoglutarate Dehydrogenase ComplexLuminescent ProteinsMicroRNAsProtein-Lysine 6-OxidaseRed Fluorescent ProteinRNA Interference3' Untranslated RegionsCre recombinaseenhanced green fluorescent proteinExtracellular Matrix ProteinsFluorescent DyesGreen Fluorescent ProteinsIntegrasesKetoglutarate Dehydrogenase ComplexLox protein, mouseLuminescent ProteinsMicroRNAsProtein-Lysine 6-OxidaseRed Fluorescent Protein

Identifiers

PMID18840295
PMCPMC2569932
OpenAlexW2095144494

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.